About this trial
This is an observational, prospective, multi-center registry, aiming at building a risk stratification for malignant inherited ventricular arrhythmias, including Brugada syndrome(Brs)、Long QT syndrome(LQTS)、Short QT syndrome(SQTS)、Early repolarization syndrome(ERS) and Catecholaminergic polymorphic ventricular tachycardia(CPVT). 500 participants will be recruited from 10 centers in China, with clinical data to be abstracted from medical records, and blood samples to be collected for finding related genes and promising risk indicators. The follow-up should be made every 6 months.
Eligibility criteria
Qualifiers
diagnosed as Brugada syndrome(Brs)、Long QT syndrome(LQTS)、Short QT syndrome(SQTS)、Early repolarization syndrome(ERS) or Catecholaminergic polymorphic ventricular tachycardia(CPVT).
Disqualifiers
patients were enrolled by other clinical trials.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
China National Center for Cardiovascular Diseases
Lead sponsor
Renmin Hospital of Wuhan University
Collaborator
The First Affiliated Hospital with Nanjing Medical University
Collaborator
Second Affiliated Hospital of Nanchang University
Collaborator
Sir Run Run Shaw Hospital
Collaborator
West China Hospital
Collaborator
Beijing Anzhen Hospital
Collaborator
General Hospital of Shenyang Military Region
Collaborator
Xuzhou Central Hospital
Collaborator
First Affiliated Hospital, Sun Yat-Sen University
Collaborator